Abrdn World Healthcare Fund (THW)

The immediate outlook is neutral, as the fund has recently recovered from a significant low to trade near its 52-week highs, yet the underlying business quality remains severely compromised. Over the last nine years, the asset has suffered a catastrophic 26.7% cumulative decline, driven by four consecutive years of negative annual returns, including a brutal 21.4% drop in the most recent year. This persistent multi-year deterioration suggests a structural issue within the healthcare sector or the fund's specific holdings that outweighs any temporary price recovery. While the valuation appears cheap at a 6.4x trailing P/E, this discount reflects the market's verdict on the deteriorating fundamentals rather than a margin of safety. The income profile is also misleading; while the headline yield exceeds 10%, the payout ratio sits at 66%, indicating that nearly two-thirds of earnings are being distributed. Given the aggressive earnings contraction, this yield is likely unsustainable and risks becoming a NAV erosion trap. Investors should avoid this security until there is clear evidence of a reversal in the multi-year decline.